{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-016391","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.758885+00:00","generated_at":"2026-05-29T01:06:22.895396+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Path reports preclinical data for BP1001-A: enhanced insulin sensitivity in obesity/T2D models","bullets":["BP1001-A reduced Grb2 protein expression in myoblast cells and increased p-AKT and p-FOXO-1 in myoblast and hepatoma cells.","Data confirm mechanism of action via insulin/PI3K/AKT pathway; supports BP1001-A as obesity/T2D treatment.","Animal studies initiated; if successful, Phase 1 clinical trial planned for 2025.","CEO cites unmet need from existing weight-loss drugs failing in obese T2D patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-016391","json":"https://secwatch.observer/filing/0001558370-24-016391.json","markdown":"https://secwatch.observer/filing/0001558370-24-016391.md","text":"https://secwatch.observer/filing/0001558370-24-016391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024016391/0001558370-24-016391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024016391/bpth-20241219x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:06:22.895396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}